Specialising in cancer and supportive care – pathologies associated with cancerology, chemotherapy and radiotherapy complications and opportunistic infections that develop in immunocompromised patients – BioAlliance Pharma conceives and develops innovative drugs mainly for hospital use, some of which target rare or orphan diseases.
Our targeted approaches, in areas where medical needs are insufficiently met, contribute to overcoming drug resistance and improving health and quality of life for patients.
BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation with patients’ needs.
13 May 2013
15 April 2013
15 April 2013
29 May 2013
Investor Breakfast - With BioAlliance Pharma Management team - By invitation only (for more information: contact@bioalliancepharma.com) - From 8:30 am to 10:00 am, Company's headoffice - 49, boulevard du General Martial Valin - 75015 Paris
25 June 2013
Investor Lunch - With BioAlliance Pharma Management team - By invitation only (for more information: contact@bioalliancepharma.com)
26 June 2013
Annual General Meeting - 4.30 pm - Company's headoffice - 49, boulevard du General Martial Valin - 75015 Paris